Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Baxter Selects Global Headquarters for Baxalta | Contract Pharma

What are you searching for?

Sign in
Breaking News

Baxter Selects Global Headquarters for Baxalta

Secures long-term lease in Bannockburn, IL

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Baxalta Inc., the biopharma company that will separate from Baxter in mid-2015, will be headquartered in Bannockburn, IL. The lease agreement for the approximately 260,000 sq.-ft. facility extends more than 10 years.
 
Upon completion of the separation, Baxalta will have approximately $6 billion in global revenues and will continue its efforts to provide therapeutic treatments for people with rare conditions, chronic diseases or limited treatment options. Supported by advanced technical and manufacturing expertise, Baxalta’s broad pipeline is built on a legacy of innovation in bleeding disorders and immunology, and is expanding to address unmet medical needs in niche areas of oncology, as well as technology platforms such as gene therapy.
 
”Selecting Baxalta’s global headquarters is a key milestone on our journey to becoming a leading, independent biopharmaceutical company, and reaffirms our commitment to Northern Illinois and our strong employee base here,” said Ludwig Hantson, Ph.D., president of Baxter BioScience, who will be chief executive officer of Baxalta.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics